Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy.

Geisen, Will R; Berger, Justin; Schwartz, Chelsea; Reddy, Abhimanyu; Rai, Balaj; Wadih, George; Peck, Joshua

Geisen, Will R; Berger, Justin; Schwartz, Chelsea; Reddy, Abhimanyu; Rai, Balaj; Wadih, George; Peck, Joshua.

Geisen WR; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
Berger J; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
Schwartz C; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
Reddy A; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
Rai B; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
Wadih G; The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
Peck J; Ohio Gastroenterology and Liver Institute, Cincinnati, OH, United States.

IDCases ; 22: e00962, 2020.

Article in English | MEDLINE | ID: covidwho-778921

ABSTRACT

ABSTRACT

The novel coronavirus-2019 (COVID-19) has caused a global pandemic of historical proportions, infecting millions of people worldwide. Due to its high mortality rate and a paucity of clinical data, experimental therapies have been utilized with uncertain success and, unfortunately, poor outcomes. We describe a gentleman who was treated with experimental therapies and subsequently developed cytomegalovirus colitis and hypovolemic shock. Additionally, this case validates colonoscopy as a mode to rule out concurrent infectious etiologies causing diarrhea in COVID-19-positive patients.

Keywords

COVID-19; Colitis; Endoscopy; Immunocompromised

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Etiology study / Prognostic study Language: English Journal: IDCases Year: 2020 Document Type: Article Affiliation country: J.idcr.2020.e00962

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google